Eli Lilly and Company financials
Key figures from Eli Lilly and Company's filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $23.0B | $15.6B | +47.7% |
| Net income | $7.1B | $5.7B | +25.3% |
| Gross margin | 85.8% | 84.3% | +1.5 pts |
| Operating margin | — | — | — |
| Net margin | 30.9% | 36.4% | -5.5 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2025 | $65.2B | $20.6B | 31.7% | — | $22.95 |
| FY Dec 2024 | $45.0B | $10.6B | 23.5% | — | $11.71 |
| FY Dec 2023 | $34.1B | $5.2B | 15.4% | — | $5.80 |
| FY Dec 2022 | $28.5B | $6.2B | 21.9% | — | $6.90 |
| FY Dec 2021 | $28.3B | $5.6B | 19.7% | — | $6.12 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.